Cargando…
A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
BACKGROUND: Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. METHODS: An initial...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886839/ https://www.ncbi.nlm.nih.gov/pubmed/35232487 http://dx.doi.org/10.1186/s40545-022-00414-2 |
_version_ | 1784660766435049472 |
---|---|
author | Elezbawy, Baher Fasseeh, Ahmad Nader Sedrak, Amal Eldessouki, Randa Gamal, Mary Eldebeiky, Mariam Amer, Hanaa Akeel, Shimaa Morsy, Ahmad Amin, Amira Shafik, Amr Abaza, Sherif Kaló, Zoltán |
author_facet | Elezbawy, Baher Fasseeh, Ahmad Nader Sedrak, Amal Eldessouki, Randa Gamal, Mary Eldebeiky, Mariam Amer, Hanaa Akeel, Shimaa Morsy, Ahmad Amin, Amira Shafik, Amr Abaza, Sherif Kaló, Zoltán |
author_sort | Elezbawy, Baher |
collection | PubMed |
description | BACKGROUND: Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. METHODS: An initial list of criteria was developed through a literature review complemented by local expert interviews. Price or cost-related criteria were excluded to abide by the national regulations of the tender process. Next, a workshop hosting diversified stakeholders representing different governmental bodies was held. Anonymous voting was used to rank and weigh the criteria as well as assigning scores. Price was added as a separate step to identify best option based on price per point. The tool was then tested on a national tender sample of off-patent oncology medicines to assess its performance, and it was readjusted accordingly in a second workshop. RESULTS: Seven non-price criteria were selected, including use in reference countries (23.49% weight), equivalence with the reference product (18.79%), manufacturing quality (15.53%), provision of pharmacovigilance services (12.94%), supply reliability (10.78%), previous use in local settings (9.8%) and macroeconomic benefit (8.67%). A medicine receives a score ranging from 0 to 100% of each criterion’s weight. The aggregated score is calculated on a hundred-point scale. Based on participants’ consensus, an overall score of 65 was set as a cut-off for passing the technical eligibility phase of the tendering process. Any product receiving a lower score would be disqualified from the tender. For qualified products, the lower price per point represents preferential option for the national tender. CONCLUSIONS: The created MCDA tool is capable of objectively comparing similar off-patent oncology medicines by considering multiple value attributes and providing reliable scoring functions for each. |
format | Online Article Text |
id | pubmed-8886839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88868392022-03-17 A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt Elezbawy, Baher Fasseeh, Ahmad Nader Sedrak, Amal Eldessouki, Randa Gamal, Mary Eldebeiky, Mariam Amer, Hanaa Akeel, Shimaa Morsy, Ahmad Amin, Amira Shafik, Amr Abaza, Sherif Kaló, Zoltán J Pharm Policy Pract Research BACKGROUND: Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. METHODS: An initial list of criteria was developed through a literature review complemented by local expert interviews. Price or cost-related criteria were excluded to abide by the national regulations of the tender process. Next, a workshop hosting diversified stakeholders representing different governmental bodies was held. Anonymous voting was used to rank and weigh the criteria as well as assigning scores. Price was added as a separate step to identify best option based on price per point. The tool was then tested on a national tender sample of off-patent oncology medicines to assess its performance, and it was readjusted accordingly in a second workshop. RESULTS: Seven non-price criteria were selected, including use in reference countries (23.49% weight), equivalence with the reference product (18.79%), manufacturing quality (15.53%), provision of pharmacovigilance services (12.94%), supply reliability (10.78%), previous use in local settings (9.8%) and macroeconomic benefit (8.67%). A medicine receives a score ranging from 0 to 100% of each criterion’s weight. The aggregated score is calculated on a hundred-point scale. Based on participants’ consensus, an overall score of 65 was set as a cut-off for passing the technical eligibility phase of the tendering process. Any product receiving a lower score would be disqualified from the tender. For qualified products, the lower price per point represents preferential option for the national tender. CONCLUSIONS: The created MCDA tool is capable of objectively comparing similar off-patent oncology medicines by considering multiple value attributes and providing reliable scoring functions for each. BioMed Central 2022-03-01 /pmc/articles/PMC8886839/ /pubmed/35232487 http://dx.doi.org/10.1186/s40545-022-00414-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Elezbawy, Baher Fasseeh, Ahmad Nader Sedrak, Amal Eldessouki, Randa Gamal, Mary Eldebeiky, Mariam Amer, Hanaa Akeel, Shimaa Morsy, Ahmad Amin, Amira Shafik, Amr Abaza, Sherif Kaló, Zoltán A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt |
title | A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt |
title_full | A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt |
title_fullStr | A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt |
title_full_unstemmed | A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt |
title_short | A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt |
title_sort | multi-criteria decision analysis (mcda) tool for purchasing off-patent oncology medicines in egypt |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886839/ https://www.ncbi.nlm.nih.gov/pubmed/35232487 http://dx.doi.org/10.1186/s40545-022-00414-2 |
work_keys_str_mv | AT elezbawybaher amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT fasseehahmadnader amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT sedrakamal amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT eldessoukiranda amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT gamalmary amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT eldebeikymariam amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT amerhanaa amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT akeelshimaa amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT morsyahmad amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT aminamira amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT shafikamr amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT abazasherif amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT kalozoltan amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT elezbawybaher multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT fasseehahmadnader multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT sedrakamal multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT eldessoukiranda multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT gamalmary multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT eldebeikymariam multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT amerhanaa multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT akeelshimaa multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT morsyahmad multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT aminamira multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT shafikamr multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT abazasherif multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt AT kalozoltan multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt |